World Cancer Day
Ìý
Ìý
Harnessing our own biology
A key strand ofÌýour approach to new cancer treatments, is to explore how we can useÌýour own biology to our advantage - empowering immune cells, proteins and genes to recognise and eliminate cancer. Essentially usingÌýliving cells, their components or products as the basis of a therapy.
Further hope for base-edited T-cell therapy to treat resistant leukaemia
Three young patients with relapsed T-cell leukaemia have now been treated with base-edited T-cells, as part of a ‘bench-to-bedside’ collaboration between °×С½ãÂÛ̳ and Great Ormond Street Hospital for Children (GOSH).
Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival
A global study has shown that the cancer immunotherapy atezolizumab significantly improved overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy.
Exploring ways to treat kidney cancer using patients’ own cells
In a new °×С½ãÂÛ̳-GSK collaboration,Ìýresearchers will investigate the role of a type of white blood cell within our immune system called a B regulatory cell, known as Breg, in kidney cancer and how the tumour microenvironment influences its formation.Ìý
Engineering better outcomes
We lookÌýbeyond the biomedicine field to leverage theÌýstrenths of our entire university - embracing a new era ofÌýengineering and computation to advance the detection, diagnosis, treatment and management of cancer.
Artificial intelligence helps to simplify lung cancer risk prediction
Machine learning models to identify the simplest way to screen for lung cancer have been developed by researchers from °×С½ãÂÛ̳ and the University of Cambridge, bringing personalised screening one step closer.
MRI scans improve prostate cancer diagnosis in screening trial
Using MRI as a screening test alongside PSA density allowed detection of cancers that would have been missed by the blood test alone, according to new research from °×С½ãÂÛ̳, °×С½ãÂÛ̳H and King’s College London.
Potent anti-cancer therapy created using ‘click chemistry’
A potent anti-cancer therapy has been created using Nobel prize-winning 'click chemistry', where molecules click together like LEGO bricks, in a new study by °×С½ãÂÛ̳ and Stanford University researchers.
Leaving no one behind
One of °×С½ãÂÛ̳'sÌýfounding principles is to achieve the greatest good for the greatest number of people. Being in the heart of London, serving aÌýdiverse population, we are determined to leave no one behind.Ìý
Better use of existing drugs increases cervical cancer survival and reduces recurrence
A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in INTERLACE phase III trial results presented by researchers from °×С½ãÂÛ̳ and °×С½ãÂÛ̳H at recent ESMO conference.
Clinical trial results give new hope for children with rare gliomas
A collaboration of researchers, led by °×С½ãÂÛ̳ and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial (TADPOLE-G) for the treatment of BRAF mutated low-grade paediatric gliomas.
Health policy research at °×С½ãÂÛ̳ boosted by over £20m from NIHR
°×С½ãÂÛ̳ has been awarded funding worth an estimated £20m for Policy Research Units by the National Institute of Health and Care Research (NIHR) to support research into health issues including early cancer diagnosis, mental and reproductive health.
Training and supporting the next generation
°×С½ãÂÛ̳'s is a global leader in research and education. Our scientific community is dedicated to discovering new techniques in cancer detection and treatment that can make a real differenceÌýto the lives of cancer patients.Ìý
Developing CAR T immunotherapy to treat glioblastoma
PhD student, Morgan Palton, talksÌýabout herÌýimmunotherapy research and the °×С½ãÂÛ̳ CAR T programme at °×С½ãÂÛ̳, plusÌýher experiences studying ourÌýCancer MSc course.Ìý
New approaches to understanding and treating brain tumours
Dr Lucy Brooks Ìýis researching radioresistance inÌýglioblastoma -ÌýÌýlooking at how to manipulate tumour cells to make them more responsive to treatment.Ìý
Breakthrough Cervical Cancer Trial
Abbie was 27 years old when she was diagnosed with cervical cancer. She took part in a °×С½ãÂÛ̳-led clinical trial (INTERLACE) which is set to change the way the disease is treated across the world. The trial results showed that aÌýcourse of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer.
To find out more about the trial, we spoke withÌýAbbie, Dr Mary McCormack, consultant medical oncologist at °×С½ãÂÛ̳H and lead investigator for the INTERLACE trialÌýand Simran Vaja, one of the statisticians at the Cancer Research UK & °×С½ãÂÛ̳ Cancer Trials Centre tasked with making sense of the data.
Ìý
Patient stories from our Cancer Trials Centre
These patients were offered CAR T-cell therapy as part of a clinical trial at °×С½ãÂÛ̳H when their previous treatments for lymphoma or leukaemia had proved unsuccessful. The therapy involves collecting some of a patient’s immune cells, genetically engineering them in a lab so they are better able to target cancer, and then putting them back into the patient's body during a process called 'infusion'.
Public lecture series catch up
Find out about the process of lung cancer evolution and how to better treat it withÌýDr Mariam Jamal-HanjaniÌýand Dr Claire RoddieÌýdiscusses the science of biohacking -Ìýreprogramming theÌýimmune system to recognise and combat cancer cells.
Ìý